Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

4f-MPH

4f-MPH molecule structure4f-MPH molecule structure
Chemical Class

4f-MPH belongs to the piperidine chemical class and is the 4-fluoro derivative of methylphenidate1. It had appeared on the recreational market by November 2015.2 It produces long-lasting increases in energy and alertness and is potent at low doses. Reports differ on its recreational effects, with some describing little euphoria and others describing greater euphoria than methylphenidate. It is considered likely to be habit-forming.

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold5 mg
Light5-10 mg
Moderate10-15 mg
Strong15-20 mg
Heavy20+ mg

Duration

Onset30-60 minutes
Peak2-4 hours
Offset1-2 hours
After Effects5-10 hours
Total4-8 hours

Subjective Effects

Subjective Effects not written up yet

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Mandelin(MD)
yellow2 → orange2
Liebermann(LB)
white → yellow1
Morr(MO)
pink2 → green1
Simons(SI)
orange1 → blue2
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

4F-MPH inhibits dopamine and norepinephrine reuptake3, reducing their clearance by transporters and increasing their availability between nerve cells. Pharmacological testing indicates that this activity is substantially stronger in the (±)-threo isomer than in the (±)-erythro isomer.3 In rat brain synaptosome uptake assays, both racemates showed little activity at the serotonin transporter.3

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
With consecutive use over extended periods, acute tolerance to 4F-MPH develops gradually, increasing the dose required to produce the same effects. Tolerance is reported to develop faster than with methylphenidate, although it is also described as lacking significant tolerance; no timeframe for full tolerance is specified.

Harm Potential

Addiction & Dependence

Psychological

High

4F-MPH has abuse potential on par with amphetamine or MDMA due to its euphoric effects and action upon dopamine transporters. Some users have become addicted to this substance, and compulsive redosing is reported, particularly at high doses or with non-oral routes of administration.

Toxicity

Cardiovascular

Acute cardiovascular effects including abnormal heartbeat and vasoconstriction occur during use; excessive stimulation may result in dangerous increases in blood pressure and heart strain, particularly at higher doses or in combination with other stimulants.

Psychosis Risk

Risk of delusions, mania, and psychosis has been noted, particularly when combined with dissociatives. The substance may carry inherent psychosis risk at higher doses.

Seizure Risk

Seizures have been mentioned as a potential risk in extreme cases, particularly in combination with certain other substances.

History & Culture

4F-MPH was investigated alongside other analogues of (±)-threo-methylphenidate as a potential therapeutic for cocaine addiction.3…

Legality

By Country

Illegal4
Germany flagGermanyIllegal (analog/blanket ban)
Switzerland flagSwitzerlandIllegal
Turkey flagTurkeyIllegal
United Kingdom flagUnited KingdomIllegal
Controlled / restricted1
United States flagUnited StatesRestricted
Legal / decriminalized1
Italy flagItalyDecriminalized

References

Citations

  1. The Psychonauts’ World of Cognitive Enhancers. Frontiers in Psychiatry (2020). https://doi.org/10.3389/fpsyt.2020.5467961
  2. Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-/threo- and (±)-/erythro- diastereomers.. Drug Testing and Analysis (2017). https://doi.org/10.1002/dta.21671
  3. Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers. Drug Testing and Analysis (2017). https://doi.org/10.1002/dta.2167123456
  4. Ministero della Salute — Tabelle delle sostanze stupefacenti e psicotrope, Tabelle allegate al Testo unico. salute.gov.it (n.d.). https://www.salute.gov.it/new/it/tema/medicinali-stupefacenti-e-precursori-di-droghe/tabelle-delle-sostanze-stupefacenti-e/?paragraph=01
  5. Ministero della Salute — TABELLA I, current schedule updated through D.M. 28 aprile 2026. salute.gov.it (n.d.). https://www.salute.gov.it/new/sites/default/files/TABELLA%20I%20DM%2028%20Aprile%202026.xlsx1
  6. Ministero della Salute, Decreto 5 ottobre 2021 — Inserimento nella tabella I di nuove sostanze psicoattive (21A06118). gazzettaufficiale.it (n.d.). https://www.gazzettaufficiale.it/atto/vediMenuHTML?atto.codiceRedazionale=21A06118&atto.dataPubblicazioneGazzetta=2021-10-18&tipoSerie=serie_generale&tipoVigenza=originario1
  7. D.P.R. 9 ottobre 1990, n. 309 — current article 73. normattiva.it (n.d.). https://www.normattiva.it/uri-res/N2Ls?urn:nir:presidente.repubblica:decreto:1990-10-09;309~art73!vig=1
  8. D.P.R. 9 ottobre 1990, n. 309 — current article 75. normattiva.it (n.d.). https://www.normattiva.it/uri-res/N2Ls?urn:nir:presidente.repubblica:decreto:1990-10-09;309~art75!vig=1
  9. 19/7/2019 tarihli ve 1335 sayılı Cumhurbaşkanı Kararı ve eki Liste — Resmî Gazete, 20 Temmuz 2019, Sayı 30837. resmigazete.gov.tr (n.d.). https://www.resmigazete.gov.tr/eskiler/2019/07/20190720-19.pdf1
  10. Uyuşturucu Maddelerin Murakabesi Hakkında Kanun, Kanun No. 2313 — current consolidated text. mevzuat.gov.tr (n.d.). https://www.mevzuat.gov.tr/MevzuatMetin/1.3.2313.pdf1

Further Reading

  1. Luethi et al. 2018 - Pharmacological profile of methylphenidate-based designer drugs

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 4f-MPH article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.